Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis (TOPAZ Registry)

This study has been withdrawn prior to enrollment.
(Did not meet enrollment goals)
Sponsor:
Information provided by:
ArthroCare Corporation
ClinicalTrials.gov Identifier:
NCT00420875
First received: January 9, 2007
Last updated: July 6, 2011
Last verified: July 2011
  Purpose

To determine the magnitude of improvement for pain and function symptoms over a two year period after enrollment into the registry study in patients presenting with chronic heel pain and receiving standard of care treatment. Standard of care will include traditional conservative care measures, ESWT, radiofrequency-based plasma microdebridement, scalpel debridement and/or surgical release.


Condition Intervention Phase
Plantar Fasciosis, Achilles Tendinosis
Device: TOPAZ MicroDebrider
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: "Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis"

Resource links provided by NLM:


Further study details as provided by ArthroCare Corporation:

Primary Outcome Measures:
  • Ankle Hind Foot Scale (AHS) [ Time Frame: 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual Analog Scale (VAS), SF-36 Quality of Life, Patient Satisfaction [ Time Frame: 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 90
Study Start Date: June 2007
Intervention Details:
    Device: TOPAZ MicroDebrider
    The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
Detailed Description:

Several million Americans receive treatment for heel pain each year, with more than two million patients treated each year for plantar fasciitis and fasciosis alone.(2) Conservative treatment options for recalcitrant heel pain include rest, stretching, strengthening and massage, progressing to non-steroidal anti-inflammatory drugs (NSAIDs), cox-2 inhibitors, steroid injections or iontophoresis with continued recalcitrance.(3;4) Orthotics, heel cups, night splints and plantar strapping are other conservative options frequently recommended by treating physicians.(4) Patient outcomes and response to conservative measures is usually positive, with non-responsive cases, approximately 2% - 10% of all presenting cases, receiving surgical care. Extracorporeal shockwave treatment (ESWT) has recently been advocated for the recalcitrant cases and has shown to be effective in 60-80 percent of the cases.(5-7) In general, non-surgical treatment of plantar fasciosis and tendinosis is believed to be unsuccessful, so that surgical treatment is required in about 25% of patients; however, results of traditional surgical treatments have been reported to deteriorate with time.(8)

Clinical experience following RF-based plasma microtenotomy has demonstrated excellent success in treating chronic, refractive tendinosis of the lateral epicondyle in the elbow.(9) The investigators reported that this technique was technically simple to perform and was much less invasive than conventional surgery. Patients had a rapid and uncomplicated recovery and reported minimal to no pain 7-10 days following the procedure; their pain relief persisted or improved through 24 months. Magnetic resonance imaging correlated well with clinical results. The RF-based plasma microtenotomy procedure is also being used successfully in tendons in the shoulder, knee, foot and ankle and in the plantar fascia. A randomized controlled study was conducted with the aim of determining whether bRF-based microtenotomy was effective for treating chronic supraspinatus tendinosis (10). Longitudinal postoperative recovery through one year for patients treated using RF-based plasma microtenotomy was compared to patients undergoing subacromial decompression. Both patient groups demonstrated significant improvement after each respective procedure and longitudinal recovery profiles were statistically similar. Early experience using this procedure for foot and ankle tendons, including the Achilles tendon, posterior tibial tendon, peroneal tendon, and plantar fascia revealed over 90% good to excellent results, reflecting the results shown by patients treated for tendinosis in the elbow (11)

Further investigation of optimal placement of this surgical approach into the standard of care treatment paradigm for treating plantar fasciosis and Achilles tendinosis would be beneficial. It is not known whether this RF-based plasma microsurgery might be more optimally placed earlier on within the standard of care treatment algorithm.

The purpose of this study is to determine the magnitude of improvement for pain and functional symptoms over a two year period after enrollment into the registry study in patients presenting with chronic heel pain and undergoing standard of care treatment. Standard of care will include traditional conservative care measures, ESWT, radiofrequency-based plasma microdebridement, scalpel debridement and/or surgical release.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is at least 18 years of age
  • Subject's history and physical examination pinpoints anatomic origin of heel pain as associated with plantar fasciosis (tenderness with palpation and local pressure over the medial calcaneal tuberosity on passive dorsiflexion) or Achilles tendinosis (tenderness upon palpation and local pressure at the insertion site)
  • Subject (or guardian) must sign IRB approved informed consent form
  • Subject is willing and able to complete required follow-up

Exclusion Criteria:

  • Previous fascia surgery on pathology to be treated by this study
  • Multiple anatomic origins of heel pain in foot to be treated by study
  • History or documentation showing Type I and Type II Diabetes Mellitus
  • Physical findings and documentation of coagulopathy, infection, tumor or other systemic disease(s)
  • History or documentation showing peripheral vascular disease or autoimmune disease
  • History or documentation of fibromyalgia
  • Subject is currently participating in another drug/device study related to the injured plantar fascia or Achilles tendon
  • Pregnant or pregnant suspected subjects prior to treatment
  • Subject is incapable of understanding or responding to the study questionnaires
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00420875

Locations
United States, Arizona
Foot Care Physicians
Mesa, Arizona, United States, 85204
United States, California
Foot and Ankle Institute of Santa Monica
Santa Monica, California, United States, 90403
United States, Georgia
Foot and Ankle Clinic of Oakwood
Oakwood, Georgia, United States, 30566
Sponsors and Collaborators
ArthroCare Corporation
Investigators
Principal Investigator: Babak Baravarian, DPM Foot and Ankle Institute of Santa Monica
  More Information

Additional Information:
Publications:

Responsible Party: Dr. Tara Waterman, Director of Medical Affairs, ArthroCare Corporation
ClinicalTrials.gov Identifier: NCT00420875     History of Changes
Other Study ID Numbers: SM-706WW
Study First Received: January 9, 2007
Last Updated: July 6, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by ArthroCare Corporation:
plantar fasciitis
plantar fasciosis
Achilles tendinosis
Achilles tendinitis
heel pain
fasciosis
fasciitis
tendinosis
tendinitis
conservative treatment

Additional relevant MeSH terms:
Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Tendon Injuries
Wounds and Injuries

ClinicalTrials.gov processed this record on April 16, 2014